Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing ...
The US Food and Drug Administration (FDA) has granted Roche a breakthrough therapy designation for its breast cancer therapy ...
(Bloomberg) — Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease ...
By Pierre Bertrand Roche said that the U.S. Food and Drug Administration has designated its Inavolisib breast cancer treatment as a breakthrough therapy.
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY ...
Roche RHHBY obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult ...
(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) and its U.S. Unit Genentech announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for ...
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options 1,2 Additional analyses of INAVO120 will be presented in ...
AstraZeneca and Daiichi Sankyo will discuss with regulators the latest DESTINY-Breast06 data presented at ASCO in the hopes ...